NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — Druggability Technologies USA today announced that Dr. John E. Friend II has been named as Chief Medical Officer.
Druggability Technologies USA has been engaged by Druggability Technologies Holding (DRGT) to assist with the clinical development of all human trials for DRGT.
DRGT is a specialty pharmaceutical company that utilizes its proprietary Super-API technology to generate high-value pharmaceutical products that deliver clinically meaningful improvement in efficacy and safety. Without chemical modification, the technology provides solutions for dose delivery, bioavailability, solubility and other performance limiting issues that can improve efficacy, the side-effect and toxicity profiles of drugs by reducing total administered dose.
Dr. John E. Friend, II, M.D. brings more than 16 years of leadership experience in the biopharmaceutical industry to DRGT USA. Most recently he was Chief Medical Officer of Cellectar Biosciences, Inc. where he was instrumental in the planning and execution of a number of oncology development programs, including rare pediatric and adult hematologic cancers. …
The post Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer appeared first on MrTopStep.com.